Since then, it feels like every pharmaceutical company has jumped at any opportunity to push their own GLP-1 drug for weight loss or weight management
AUD is a serious cause of mortality and morbidity, with more than 400 million people around the world affected by their inability to manage their alcohol consumption [2, 3]
Neurol Sci 33:875880 Valensi P, Le Devehat C, Richard J et al (2005) A multicenter, double-blind, safety study of QR-333 for the treatment of symptomatic diabetic peripheral neuropathy
It works by mimicking the action of two appetite-regulating hormones: GLP-1 (glucagon-like peptide-1) and GIP (glucose-dependent insulinotropic polypeptide)
This approach allows the body to adapt to appetite suppression and delayed gastric emptying, reducing the likelihood of side effects that may otherwise lead to treatment discontinuation
The views expressed by authors and contributors of such content are not endorsed or approved by Fay and are intended for informational purposes only
